All In Biotech

Drug Trial Radar · NCT07722884

Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

Safety and Efficacy of Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Jan 1, 2027

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Ain Shams UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs. 5 mg) on lower urinary tract symptoms (LUTS) severity and patient quality of life in men with benign prostatic hyperplasia (BPH). It also seeks to determine whether the lower tadalafil dose provides adequate symptom relief while minimizing adverse effects over a 12-week follow-up period.

Conditions

  • Safety
  • Efficacy
  • Tamsulosin
  • Monotherapy
  • Tadalafil
  • Lower Urinary Tract Symptoms
  • Benign Prostatic Hyperplasia

Interventions

  • Tamsulosin 0.4 mg + Tadalafil 2.5 mgDrug

    Patients will receive Tamsulosin 0.4 mg once daily + Tadalafil 2.5 mg once daily

  • Tamsulosin 0.4 mg + Tadalafil 5 mgDrug

    Patients will receive Tamsulosin 0.4 mg once daily + Tadalafil 5 mg once daily

  • Tamsulosin 0.4 mgDrug

    Patients will receive Tamsulosin 0.4 mg once daily (monotherapy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in International Prostate Symptom Score (IPSS) scoreTime frame: 12 weeks post-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ain Shams University

    Cairo, Cairo Governorate, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.